# Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients

> **NCT02437071** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiotherapy
- **PROCEDURE:** Radiofrequency ablation

## Key facts

- **NCT ID:** NCT02437071
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437071, "Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02437071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*